Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. BriaCell Therapeutics Corp.
  6. News
  7. Summary
    BCT   CA10778Y3023

BRIACELL THERAPEUTICS CORP.

(BCT)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BriaCell Therapeutics : to Present at the American Association for Cancer Research Annual Meeting 2021 March 30, 2021

03/31/2021 | 08:25am EDT

BERKELEY - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that it has been selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2021, a virtual meeting, held over two weeks (Week 1: April 10-15; Week 2: May 17-21).

BriaCell will be presenting the results of its analysis of clinical and pathological data of its lead candidate, Bria-IMT, a novel immunotherapy for advanced breast cancer, as monotherapy and a Phase I/IIa clinical study of Bria-IMT in combination with immune checkpoint inhibitors, including pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) and, more recently, Incyte's INCMGA00012 (under a corporate collaboration with Incyte Corporation). The patient data belong to previously-disclosed patients (i.e., no incremental numbers enrolled).

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

Forward Looking Statements

This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Company's SEC filings. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Contact:

William V. Williams

Tel: 1-888-485-6340

Email: info@briacell.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BRIACELL THERAPEUTICS CORP. -0.26% 3.79 Delayed Quote.-36.45%
INCYTE CORPORATION 0.55% 82.755 Delayed Quote.-5.01%
All news about BRIACELL THERAPEUTICS CORP.
05/11BRIACELL THERAPEUTICS  : to Participate at Upcoming Conferences and Appoints Sen..
AQ
05/10BRIACELL THERAPEUTICS  : to Participate at Upcoming Conferences and Appoints Sen..
PU
04/21BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview wi..
GL
04/12BRIACELL THERAPEUTICS  : Closes Over-Allotment Option in Connection with U.S. Pu..
MT
04/01BRIACELL THERAPEUTICS  : Investor Presentation – Spring 2021
PU
03/31BRIACELL THERAPEUTICS  : to Present at the American Association for Cancer Resea..
AQ
03/09BRIACELL THERAPEUTICS  : Announces Pricing of US$25 Million Public Offering and ..
PU
02/26BRIACELL THERAPEUTICS  : Closes US$25 Million Public Offering
MT
02/24BRIACELL THERAPEUTICS  : Overnight Priced US$25 Million Public Offering and Nasd..
MT
01/26BriaCell Presents Clinical Data at 2021 Keystone Symposium
GL
More news
Financials
Sales 2020 - - -
Net income 2020 -4,94 M -4,10 M -4,10 M
Net Debt 2020 0,28 M 0,23 M 0,23 M
P/E ratio 2020 -1,38x
Yield 2020 -
Capitalization 28,6 M 23,7 M 23,7 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 6
Free-Float 8,62%
Chart BRIACELL THERAPEUTICS CORP.
Duration : Period :
BriaCell Therapeutics Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
William V. Williams President, Chief Executive Officer & Director
Gadi Levin Chief Financial Officer & Secretary
Jamieson Bondarenko Chairman
Miguel A. Lopez-Lago Senior Director-Research & Development
Rebecca A. Taub Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRIACELL THERAPEUTICS CORP.-36.45%24
GILEAD SCIENCES, INC.17.63%86 626
WUXI APPTEC CO., LTD.13.72%60 935
VERTEX PHARMACEUTICALS-8.46%56 006
REGENERON PHARMACEUTICALS6.94%54 236
BIONTECH SE143.25%47 894